AdaptHealth (AHCO) Q3 2026 Earnings Call Transcript

AdaptHealth reported Q3 revenue of $745.6 million, up 10.9% year over year, and adjusted EBITDA of $141.9 million, $11.2 million above the midpoint of its implied guidance. It raised full-year revenue guidance to $2.88 billion–$2.90 billion and adjusted EBITDA guidance to $510 million–$525 million, while lowering free cash flow guidance to $55 million–$80 million. The quarter included a $168.2 million net loss, primarily due to a $184.8 million non-cash goodwill impairment; adjusted EBITDA margin fell to 19% from 21.7% a year earlier. The company expects to close its $235 million Diabetes Health sale in early 2027 and plans to use a significant portion of proceeds to reduce debt.

Analysis

AHCO’s quarter is a margin-repair story, not yet a broad-based growth reacceleration. The largest capitated contract supplied most organic growth, while base-business contribution remained modest; the contract’s move from loss-making to positive is encouraging, but the 20% margin goal is still a 2027 target and management’s outlook assumes no pricing amendment. The key asymmetry is utilization: if it stays above pricing assumptions or referral workflows remain costly, incremental volume can worsen economics even as revenue grows. A negotiated rate reset would be upside beyond current guidance, but should not be capitalized before terms are agreed.

The Diabetes sale can reduce leverage and remove about half of the stranded overhead over the following year, but the remaining overhead, closing timing, and weak year-to-date free cash flow limit the near-term balance-sheet benefit. Prioritizing vendor discounts over cash balances makes reported cash conversion less clean as a signal of run-rate generation. The goodwill impairment is non-cash, yet it underscores that equity-market confidence has not caught up with management’s stabilization narrative.

For MDLN, bed replacement creates execution and supply availability risk across providers, but AHCO’s stated low-single-digit bed revenue exposure and expectation of supplier reimbursement argue against assuming a material AHCO earnings hit; replacement capacity and reimbursement terms remain unverified. The manufacturer rebate discussion may relate to RMD, but contract economics and net price effects are undisclosed, so it is not a standalone signal for RMD. Near term, AHCO can react positively to guidance and operating progress; over 1–3 months, contract pricing and replacement logistics matter more; over 6–18 months, margin conversion, debt paydown, and overhead removal determine whether the turnaround is durable.

Key Decisions for Investors

• Treat AHCO as a conditional turnaround, not a clean growth compounder. Avoid chasing the quarter; consider a staged long only if subsequent reporting confirms sustained contract margin improvement and base-business growth. Falsify the thesis if contract margins reverse or EBITDA guidance is cut.
• Track the largest contract’s realized margin, utilization, labor cost per patient, and any signed pricing amendment. The 20% target is not dependent on repricing; any agreed adjustment is potential upside, not a base-case assumption.
• For credit and equity monitoring, verify Diabetes sale closing, proceeds applied to debt, and progress toward 2.5x net leverage. Reassess if closing slips, the stranded-cost run-off lags, or free cash flow remains weak after working-capital timing normalizes.
• Keep MDLN bed-replacement exposure on watch rather than shorting on this disclosure alone. Seek confirmation of affected-unit counts, replacement lead times, and reimbursement coverage; a supply bottleneck or unreimbursed field-action costs would change the risk assessment. Do not infer a material RMD earnings impact without disclosed rebate and net-pricing terms.